I期三阴性乳腺癌免疫与增殖基因特征及间质肿瘤浸润淋巴细胞与临床结局的关联
该回顾性研究纳入253例I期三阴性乳腺癌患者,评估TNBC-DX检测(核心免疫基因特征与增殖特征)及间质肿瘤浸润淋巴细胞(sTILs)与临床结局的关联。中位随访期间仅18例复发,总体3年无复发生存率为95.0%;最高CIG评分四分位组29例患者3年RFS达100%,高sTILs(>20%)组3年RFS为97.0%,而高增殖评分组3年RFS数值上较低(83%)。免疫与增殖特征呈现相反预后趋势,联合应用可能改善风险分层。
要点
- I期TNBC总体预后良好,3年RFS为95.0%,3年OS为97.9%。
- 最高CIG评分四分位组29例患者3年RFS达100%,高sTILs(>20%)组为97.0%。
- 高增殖评分与较差结局呈数值关联,3年RFS为83%。
核心结论
- 在I期TNBC中,免疫特征与增殖特征呈现相反的预后趋势,联合整合可能改善风险分层,值得进一步研究。
研究设计与样本
- 回顾性研究,纳入2016至2021年在Dana-Farber/Brigham癌症中心接受 upfront 手术及标准辅助系统治疗的连续I期TNBC患者253例(ER<10%且HER2阴性)。
- 对肿瘤组织应用TNBC-DX检测(核心免疫基因CIG特征与增殖特征),并由中心统一审阅间质肿瘤浸润淋巴细胞(sTILs)。
- 采用Kaplan-Meier法检验生物标志物与临床结局的关联。
主要发现
- 共253例患者,多数为导管癌(88.9%)和高分级(73.1%),65.2%接受辅助化疗。
- 观察到18例复发事件,总体队列3年无复发生存率(RFS)为95.0%(95%CI 92.1%-98.1%),3年总生存率为97.9%(95%CI 95.9%-100.0%)。
- 按TNBC-DX(n=117)或sTILs(n=123)分类,RFS未见显著差异。
- 最高CIG评分四分位组29例患者3年RFS为100%(95%CI 100%-100%);高sTILs(>20%)组3年RFS为97.0%(95%CI 90%-100%)。
- 高TNBC-DX增殖评分与较差结局呈数值关联,3年RFS为83%(95%CI 68%-100%)。
临床怎么用
- I期TNBC总体预后良好,但高增殖评分患者可能预后较差,最高CIG评分及高sTILs患者预后极佳,提示免疫与增殖特征联合可用于辅助风险分层。
局限性
- 回顾性研究设计,复发事件数较少(18例),统计效能有限。
- TNBC-DX和sTILs评估的样本量分别仅为117例和123例,并非全部队列。
- 部分亚组置信区间较宽,结果需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: One-third of patients with triple-negative breast cancer (TNBC) are diagnosed with stage I tumors. Biomarkers to stratify prognosis in this setting remain a major unmet need. METHODS: Tissue samples and clinicopathologic data were retrieved from consecutive patients with stage I TNBC (defined as ER <10% and HER2-negative) who underwent upfront breast surgery and received standard of care adjuvant systemic therapy at Dana-Farber/Brigham Cancer Center between 2016 and 2021. The TNBC-DX assay (Core Immune Gene [CIG] signature, proliferation signature) was applied to tumor tissue, and stromal tumor-infiltrating lymphocytes (sTILs) were centrally reviewed. Both biomarkers were tested for association with clinical outcomes using the Kaplan-Meier method. RESULTS: A total of 253 patients with stage I TNBC were included. Most tumors were ductal (88.9%) and high-grade (73.1%); 65.2% of patients received adjuvant chemotherapy. With 18 recurrence events observed, the 3-year recurrence-free survival (RFS) in the overall cohort was 95.0% (95% confidence interval [CI]: 92.1% - 98.1%) and the 3-year overall survival was 97.9% (95% CI: 95.9% - 100.0%). No significant differences in RFS were observed by TNBC-DX (n = 117 patients) or sTILs (n = 123 patients) category. However, a 3-year RFS of 100% (95% CI: 100% - 100%) was observed among the 29 patients with the highest CIG score quartile. A favorable prognosis was also observed in patients with high sTILs (>20%), who experienced a 3-year RFS of 97.0% (95% CI: 90% - 100%). Conversely, a high TNBC-DX proliferation score was numerically associated with poor outcomes, with a 3-year RFS of 83% (95% CI: 68% - 100%). CONCLUSIONS: In this retrospective study, immune and proliferative features showed opposing prognostic trends in stage I TNBC. Their integration may improve risk stratification and warrants further investigation.
引用
- Tarantino P, Li T, Paré Brunet L, et al. Association of immune and proliferation gene signatures and stromal tumor-infiltrating lymphocytes with clinical outcomes in patients with stage I triple-negative breast cancer. Eur J Cancer. 2026. PMID: 42710277. doi:10.1016/j.ejca.2026.117020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。